0001193125-16-794001.txt : 20170117 0001193125-16-794001.hdr.sgml : 20170117 20161215112633 ACCESSION NUMBER: 0001193125-16-794001 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 CORRESP 1 filename1.htm Acceleration request

Ladenburg Thalmann & Co. Inc.

December 15, 2016

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 

  Re: RXI PHARMACEUTICALS CORPORATION
       Registration Statement on Form S-1 (Registration No. 333-214199) -
       Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg Thalmann & Co., Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by RXi Pharmaceuticals Corporation that the effective date of the above-referenced registration statement be accelerated to 4:05 p.m. (Eastern Time), or as soon as practicable thereafter, on December 15, 2016, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

 

Very truly yours,

 

LADENBURG THALMANN & CO. INC.

By:   /s/ Nicholas Stergis
 

Name: Nicholas Stergis

Title: Managing Director